Results 131 to 140 of about 174,156 (175)

Pirtobrutinib in Chinese patients with relapsed or refractory B-cell malignancies: A single-arm, open-label, phase 2, multicenter trial. [PDF]

open access: yesInt J Cancer
Liu Y   +13 more
europepmc   +1 more source

Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous Urticaria: The RILECSU Phase 2 Randomized Clinical Trial.

open access: yesJAMA Dermatol
Giménez-Arnau A   +7 more
europepmc   +1 more source

Identification of Bruton tyrosine kinase mutations in 12 Chinese patients with X‐linked agammaglobulinaemia by long PCR‐direct sequencing

open access: closedInternational Journal of Immunogenetics, 2006
SummaryX‐linked agammaglobulinaemia (XLA) is an immunodeficiency caused by Bruton tyrosine kinase (BTK) gene mutations. The disease is characterized by recurrent bacterial infections and profound hypogammaglobulinemia with marked reduction or lack of mature B‐cells in the peripheral blood.
Lee, TL   +7 more
semanticscholar   +7 more sources

Mutation analysis in Bruton's tyrosine kinase, the X-linked agammaglobulinaemia gene, including identification of an insertional hotspot

open access: closedHuman Molecular Genetics, 1995
Chaim M. Roifman   +7 more
semanticscholar   +5 more sources

Home - About - Disclaimer - Privacy